Blenrep (belantamab mafodotin) plus BorDex showed statistically significant progression-free survival (PFS) benefit versus daratumumab plus BorDex
First-in-class AKT inhibitor has potential to reshape treatment for breast cancer patients
Decision on EU marketing authorisation expected for momelotinib by early 2024
Approval based on results from the Phase 3 KEYNOTE-859 trial, which demonstrated significant improvement in overall survival in these patients versus chemotherapy alone
XTANDI becomes the first and only androgen receptor signaling inhibitor approved for use with or without a GnRH analog therapy in nonmetastatic castration-sensitive prostate cancer
Approval based on results from TOPAZ-1 global Phase III trial and a Chinese patient
Yesafili, received marketing authorization approval from the European Commission for the European Union
Total transaction value of the divestment is Rs. 3,660 million
The agreement demonstrates a shared commitment to advance precision medicine and improve patient outcomes in the region
In 2022, darolutamide was FDA-approved in combination with docetaxel chemotherapy for adults with metastatic hormone-sensitive prostate cancer
Subscribe To Our Newsletter & Stay Updated
